One-third of target group now vaccinated against monkeypox 10,440 monkeypox vaccinations have already been administered in the Netherlands in the last few weeks. That represents about one-third of the target group currently eligible to get the vaccine against monkeypox. Science Photo Library / ANP
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
National Heatwave Plan no longer in operation as of 17 August 2022 As of Wednesday, 17 August 2022, the National Heatwave Plan is no longer in operation. Although the period of persistent heat is over, temperatures will remain high over the coming days.
National Heatwave Plan to be activated on 10 August After consulting the Royal Netherlands Meteorological Institute (KNMI), RIVM has decided to activate the National Heatwave Plan in all Dutch provinces as of 10 August 2022.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
Breast milk as indicator of environmental pollutants The 6th worldwide study into Persistent Organic Pollutants (POPs) in breast milk is about to commence.
The National Immunisation Programme in the Netherlands: Developments in 2013 Annually RIVM provides an overview of key events and developments in the National Immunisation Programme (NIP).
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.